Cochrane’s Governing Board is pleased to announce, with effect from 1 June 2021, the appointment of Judith Brodie as our new interim Chief Executive Officer. Judith will lead Cochrane as the organisation undergoes its search for a permanent CEO and ensure a smooth transition.

Governing Board Co-Chairs, Tracey Howe and Catherine Marshall welcomed Judith’s appointment: "Judith is a seasoned, well-respected and proven interim Chief Executive with an exceptional record in non-profit organisations and brings expertise in finance, fundraising, public and patient involvement in healthcare and marketing. Judith is a great fit for Cochrane and is well qualified to lead Cochrane as we drive a programme of change at this crucial time of global health and economic challenge."

On her appointment, Judith, said: "I am delighted to be joining Cochrane and being part of this global collaboration.  The work of Cochrane has surely never been more important.  I am looking forward to meeting and working with many of Cochrane’s Group staff and contributors and the wider network over the coming months."

The Co-Chairs added, "We would also like to record our appreciation to our Editor-in-Chief, Karla Soares-Weiser, for taking on the additional role of Acting CEO, as well as to Toby Lasserson who has been Acting Editor-in-Chief and Chris Champion who took on additional responsibilities for governance and finance."

On behalf of Cochrane’s Governing Board, we warmly welcome Judith to this important leadership role, she will work alongside the Governing Board and the Senior Management Team and we look forward to her joining us for our forthcoming Governance Meetings on 22nd and 24th June.

Judith will also introduce herself at the Editor in Chief monthly webinars on June 3rd, register here to take part.

Read more about Judith Brodie here

Best wishes,
Tracey Howe and Catherine Marshall
Governing Board Co-Chairs